Bio/Pharma News

Sep 28, 2017
By Pharmaceutical Technology Editors
AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, and Eli Lilly and Company said they are working to restore normal operations at their respective facilities and continuing recovery efforts.
Sep 28, 2017
By Pharmaceutical Technology Editors
Amgen will collaborate with China’s Simcere Pharmaceutical Group, a R&D-driven pharmaceutical company, to co-develop four biosimilars for the Chinese market.
Sep 27, 2017
By Pharmaceutical Technology Editors
FDA rejected the company’s biologics license application for its anti-rheumatoid arthritis biologic and has requested additional clinical safety data.
Sep 26, 2017
By Pharmaceutical Technology Editors
Glythera gains exclusive access to Cancer Research UK’s novel CDK11 inhibitor program for the development of ADCs conjugated using its highly stable conjugation platform, PermaLink.
Sep 26, 2017
By Pharmaceutical Technology Editors
This latest FDA approval expands the blockbuster anti-cancer biologic’s indications in oncology.
Sep 25, 2017
By Pharmaceutical Technology Editors
The collaboration will evaluate the combination of BMS’ Opdivo immunotherapy with an investigational antibody drug conjugate in development by AbbVie.
Sep 20, 2017
By Pharmaceutical Technology Editors
Under this partnership, Johnson & Johnson and BARDA will focus on the advanced development of a small-molecule drug and vaccine for the pandemic flu.
Sep 19, 2017
By Pharmaceutical Technology Editors
The partners will develop a lead anti-platelet, anti-coagulant (APAC) product for treating blood vessel wall injury. Clinical trials are set for 2019 in India.
Sep 15, 2017
By Pharmaceutical Technology Editors
European Medicines Agency’s Committee for Medicinal Products for Human Use grants a positive opinion for the approval of the biosimilar for treating breast cancer.
Sep 15, 2017
By Pharmaceutical Technology Editors
The approval marks the first biosimilar approved in the United States for treating cancers.
native1_300x100
lorem ipsum